Partnerships

High Performance Computing

Partnership website: https://eurohpc-ju.europa.eu/index_en

The partnership aims by 2027

to develop, deploy, extend and maintain a world leading federated and hyper-connected supercomputing, quantum computing, service and data infrastructure ecosystem in the EU
support the autonomous production of innovative and competitive supercomputing systems based on indigenous European components, technologies and knowledge and the development of a wide range of applications optimised for these systems
widen the use of this supercomputing infrastructure to a large number of public and private users, and support the development of key skills that European science and industry need

Draft outline of partnership proposal (May 2019, update pending)

Contact

Commission services: cnect-c2@ec.europa.eu

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

More detailed info Overview of partnerships

How to use partnerships?

orientation
Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.
networking
Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.
ecosystem analysis
Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.
steering the agenda
Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article or Check out the other testimonials

Funding programmes

Content

Tools

High Performance Computing

What are partnerships?

How to use partnerships?

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

NCP Flanders

Updates

Our Services

Legal mentions